

Notice Information: Human Medicines - Advisory

04 June 2008

Part 1. Product Information

- a) Title: EMEA recommends changes in the storage conditions for Neupro (rotigotine)
- b) Product Name/Type: Neupro Transdermal Patches (rotigotine)
- c) Active Substance: Rotigotine

Part 2. Target Audience

- a) Target Audience: Healthcare Professionals Pharmacists Wholesalers of Medicinal Products General Public

Part 3. Problem/Issue

- a) Problem/Issue: The European Medicines Agency (EMA) has recommended the immediate implementation of changes to the product information for Neupro (rotigotine), from Schwarz Pharma Ltd, stating that it must be stored in a refrigerator (at a temperature of between 2°C and 8°C). The new storage conditions are intended to reduce the possible occurrence of crystallisation of the active substance which has been reported in patches of Neupro. For further information, click [here to read the Press Release](#) and [Q&A document](#).

Part 4. Keywords

- a) Keywords: Neupro Transdermal Patches (rotigotine)